ClinicalTrials.gg
CompletedNCT01318733Updated Feb 18, 2021Results posted

Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

A Phase 3 interventional study of CD07805/47 gel 0.5% in Rosacea, sponsored by Galderma R&D. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
449
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing brimonidine in Rosacea — none open to participants now, none under way, none of them phase 3. brimonidine · Rosacea.

Enrollment
2nd of 11
449 · median 205
Started
2011
with 2 others
Phase 3
4 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
8 of 11
Galderma R&D

Among the 11 studies testing brimonidine in Rosacea, this one is the 2nd largest by enrollment, is one of 3 that started in 2011, is one of 4 in phase 3, and was the 4th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing brimonidine in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing brimonidine in Rosacea as a file.
02

Study summary

A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.

03

Conditions studied

  • Rosacea

Browse trials for

Keywords

  • Rosacea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female who is at least 18 years of age or older.
  • A clinical diagnosis of facial rosacea.
  • A Clinician Erythema Assessment (CEA) score of ≥3 at Screening and at Baseline (prior to study drug application).
  • A Patient Self Assessment (PSA) score of ≥3 at Screening and at Baseline (prior to study drug application).

Exclusion criteria

Exclusion Criteria:

  • Particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia.
  • Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression.
  • Previous refractive eye surgery such as photorefractive keratectomy (PRK), laser-assisted sub-epithelial keratectomy (LASEK), or laser-assisted in situ keratomileusis (LASIK).
  • Current treatment with monoamine oxidase (MAO) inhibitors.
  • Current treatment with barbiturates, opiates, sedatives, systemic anesthetics, or alpha-agonists.
  • Less than 3 months stable dose treatment with tricyclic anti-depressants, cardiac glycosides, beta blockers or other antihypertensive agents.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
449 participants (actual)

Study arms

  • Experimental
    CD07805/47 Gel 0.5%

    Drug: CD07805/47 gel 0.5%

Interventions

  • DrugCD07805/47 gel 0.5%

    Drug page: Brimonidine

    In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.

06

What researchers measure

Primary outcomes

  1. Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea.

    Static evaluation of erythema severity using the Clinician Erythema Assessment (CEA) - Grade/Description 0 / Clear Skin with no signs of erythema 1. / Almost clear; slight redness 2. / Mild erythema; definite redness 3. / Moderate erythema; marked redness 4. / Severe erythema; fiery redness Change in CEA from Baseline CEA (T0 at Baseline visit Day 1) at T3 of each post-baseline visit, including Day 1.

    Time frame: Over 1 year

07

Results

Posted Jan 8, 2014

Participant flow

Participant flow — Overall Study
MilestoneCD07805/47 Gel 0.5%
Started449
Completed279
Not completed170

Outcome measures

PrimaryLong Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea.

Static evaluation of erythema severity using the Clinician Erythema Assessment (CEA) - Grade/Description 0 / Clear Skin with no signs of erythema 1. / Almost clear; slight redness 2. / Mild erythema; definite redness 3. / Moderate erythema; marked redness 4. / Severe erythema; fiery redness Change in CEA from Baseline CEA (T0 at Baseline visit Day 1) at T3 of each post-baseline visit, including Day 1.

Time frame:
Over 1 year
Reported as:
Mean · scores on a scale
Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea.
scores on a scaleCD07805/47 Gel 0.5% QD
Day 1 / Hour 3-1.5 ± .88
Week 1/ Hour 3-1.4 ± .85
Month 1/ Hour 3-1.5 ± .83
Month 3 / Hour 3-1.7 ± .84
Month 6 / Hour 3-1.8 ± .88
Month 9 / Hour 3-1.7 ± .9
Month 12 / Hour 3-1.8 ± .83

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD07805/47 Gel 0.5%—12/449 (2.7%)101/449 (22.5%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventCD07805/47 Gel 0.5%
Abscess tooth w/ secondary submandibular infectionInfections and infestations1/449
Osteoarthritis of left hipMusculoskeletal and connective tissue disorders1/449
Advanced squamous cell carcinoma of the lungNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/449
COPDRespiratory, thoracic and mediastinal disorders1/449
EncephalopathyNervous system disorders1/449
Invasive ductal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/449
Distal Esophageal Schatzki's RingGastrointestinal disorders1/449
Unstable AnginaCardiac disorders1/449
Right Ovarian CystReproductive system and breast disorders1/449
Sustained Ventricular TachycardiaCardiac disorders1/449
Most frequent other events
Most frequent other events
EventCD07805/47 Gel 0.5%
FlushingVascular disorders46/449
ErythemaSkin and subcutaneous tissue disorders35/449
RosaceaSkin and subcutaneous tissue disorders24/449

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CD07805/47 Gel 0.5%
<=18 years0
Between 18 and 65 years395
>=65 years54
Age, Continuous
Age, Continuous(years)CD07805/47 Gel 0.5%
Mean50.9 ± 12.08
Sex: Female, Male
Sex: Female, Male(Participants)CD07805/47 Gel 0.5%
Female336
Male113
Region of Enrollment
Region of Enrollment(participants)CD07805/47 Gel 0.5%
United States449
08

Study locations

27 sites
  • The Laser Institute for Dermatology
    Santa Monica, California 90404, United States
  • Cherry Creek Research, Inc
    Denver, Colorado 80209, United States
  • Longmont Clinical PC
    Longmont, Colorado 80501, United States
  • Gwinnett Clinical Research Center, Inc
    Snellville, Georgia 30078, United States
  • Deaconess Clinic
    Evansville, Indiana 47713, United States
  • Compliant Clinical Research
    Olathe, Kansas 66061, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Dermcenter PC- Somerset Skin Centre
    Troy, Michigan 48084, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
  • DermResearch Center of New York, Inc
    Stony Brook, New York 11790, United States
  • Metrolina Medical Research
    Charlotte, North Carolina 27277, United States
  • Dermatology, Laser & Vein Specialists of the Carolinas
    Charlotte, North Carolina 28207, United States
  • Wilmington Medical Research
    Wilmington, North Carolina 28401, United States
  • Piedmont Medical Research
    Winston-Salem, North Carolina 27103, United States
  • DermDox
    Hazleton, Pennsylvania 18201, United States
  • Palmetto Medical Research
    Mount Pleasant, South Carolina 29464, United States
  • Rivergate Dermatology Clinical Research Center, PLLC
    Goodlettsville, Tennessee 37072, United States
  • East Tennessee Medical Research
    Johnson City, Tennessee 37604, United States
  • TriCities Medical Research
    Kingsport, Tennessee 37660, United States
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
  • Arlington Center for Dermatology
    Arlington, Texas 76011, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Progressive Clinical Research, PA
    San Antonio, Texas 78229, United States
  • Dermatology Research Center
    Salt Lake City, Utah 84124, United States
  • Wenatchee Valley Medical Center - Clinical Research Department
    Wenatchee, Washington 98801, United States
  • Madison Skin & Research, Inc.
    Madison, Wisconsin 53719, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jun 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 1 year 7 months after primary completion. A results delay was requested in Jul 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2011
First posted
Mar 18, 2011
Start
Mar 2011
Primary completionActual
Jun 2012
CompletionActual
Jul 2012
Results delay requested
Jul 23, 2012
Results first posted
Jan 8, 2014
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01318733
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Mar 18, 2011
Start date
Mar 2011
Primary completion
Jun 2012
Completion
Jul 2012
Results posted
Jan 8, 2014
Last update
Feb 18, 2021

Study contacts

Scott Clark, MD
principal investigator · Longmont Clinical PC
Lesly Davidson, MD
principal investigator · Palmetto Medical Research
Steven Davis, MD
principal investigator · Dermatology Clinical Research Center of San Antonio
Michael Donahue, MD
principal investigator · Wilmington Medical Research
Timothy Gardner, MD
principal investigator · East Tennessee Medical Research
Michael Gold, MD
principal investigator · Tennessee Clinical Research Center
Fasahat Hamzavi, MD
principal investigator · Hamzavi Dermatology
Mark Lee, MD
principal investigator · Progressive Clinicial Research, PA
Debra Liu, MD
principal investigator · Piedmont Medical Research
Keith Loven, MD
principal investigator · Rivergate Dermatology Clinical Research Center, PLLC
Michael Maloney, MD
principal investigator · Cherry Creek Research, Inc.
Angela Moore, MD
principal investigator · Arlington Center for Dermatology
George Murakawa, MD
principal investigator · Dermcenter PC - Somerset Skin Centre
Catherine Pointon, MD
principal investigator · Metrolina Medical Research
Elyse Rafal, MD
principal investigator · DermResearch Center of NewYork, Inc.
Stephen Schleicher, MD
principal investigator · DermDox
Joel Schlessinger, MD
principal investigator · Skin Specialists, PC
Leonard Swinyer, MD
principal investigator · Dermatology Research Center
Amanda Tauscher, MD
principal investigator · Compliant Clinical Research
Gary Waterman, MD
principal investigator · Deaconess Clinic
Jonathan Weiss, MD
principal investigator · Gwinnett Clinical Research Center, Inc.
Morrissa Baskin, MD
principal investigator · Wenatchee Valley Medical Center, Clinical Research Department
Steven Kempers, MD
principal investigator · Minnesota Clinical Study Center
Ava Shamban, MD
principal investigator · The Laser Institute for Dermatology
Harry Sharata, MD
principal investigator · Madison Skin & Research, Inc.
Russell Mader, MD
principal investigator · TriCities Medical Research
Girish Munavalli, MD
principal investigator · Dermatology, Laser & Vein Specialists of the Carolinas

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion